EUVIMEDEUVIMED entdecken
Crossref

EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release 2309955

Jeanette Ampudia, Mary Casis, Rosa Quinn Closser, Stephen Connelly, A J Giovannone, Valeria Marrocco, Phoi Tiet

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.1653 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Jeanette Ampudia und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that promotes immune tolerance in part by enhancing regulatory T cell (Treg) development and function of macrophages. Despite its therapeutic potential inflammatory bowel disease (IBD), clinical development of AhR modulators has been limited by the lack of potent, selective and drug-like molecules.

Methods

We evaluated EQ504, a novel small-molecule AhR modulator derived from the endogenous ligand ITE and obefazimod, a clinically validated molecule in IBD. Human immune cells were treated with each compound to assess AhR activation, regulatory T cell differentiation, and macrophage polarization. Cytokine production and phenotypic markers were analyzed to define immunoregulatory outcomes.

Results

EQ504 activated AhR in both Tregs and monocytes/macrophages. The two molecules drove distinct regulatory T cell programs: EQ504 preferentially induced FOXP3⁻ Type 1 regulatory T cells (Tr1s), whereas obefazimod promoted FOXP3+ Treg differentiation. Tr1 cells are particularly relevant in IBD due to their IL-10—mediated immunosuppression, granzyme B—dependent targeting of inflammatory antigen-presenting cells, and capacity to restrain Th1/Th17-driven inflammation while supporting mucosal repair. EQ504 also shifted macrophage polarization toward an anti-inflammatory phenotype, decreasing M1 frequencies while increasing M2 frequencies, accompanied by reduced production of pro-inflammatory cytokines including IL-12p70, TNFα, IL-6, and IL-1β.

Conclusion

These findings identify EQ504 as a potent next generation AhR modulator with a unique immunoregulatory profile. EQ504 promotes Tr1mediated immune tolerance and anti-inflammatory macrophage polarization, mechanisms highly relevant to the treatment of IBD. Funding Source N/A Topic Categories Immune Response Regulation: Cellular Mechanisms (IRC)

Zitieren

APA

Ampudia, J., Casis, M., Closser, R. Q., Connelly, S., Giovannone, A. J., Marrocco, V., & Tiet, P. (2026). EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release 2309955. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1653

Vancouver

Ampudia J, Casis M, Closser RQ, Connelly S, Giovannone AJ, Marrocco V, et al. EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release 2309955. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1653

BibTeX
@article{Ampudia2026,
  author = {Ampudia, Jeanette and Casis, Mary and Closser, Rosa Quinn and Connelly, Stephen and Giovannone, A J and Marrocco, Valeria and Tiet, Phoi},
  title = {EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release 2309955},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.1653}
}
Kostenlos starten →